SSC
REGN icon

Syverson Strege & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Syverson Strege & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10
Closed -$8.22K – 490
2023
Q1 		$8.22K Buy
+10
New +$7.54K ﹤0.01% 271

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Syverson Strege & Co's REGN Position: Q2 2023 in Review

Syverson Strege & Co sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 10 shares — an estimated $8.22K sold.

Syverson Strege & Co first reported a position in REGN in Q1 2023 and held it in 1 quarter. The position peaked at $8.22K in Q1 2023. 1,165 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

  • Syverson Strege & Co reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 10 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $8.22K.
  • Syverson Strege & Co first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Syverson Strege & Co's Regeneron Pharmaceuticals position peaked at $8.22K in Q1 2023.
  • 1,165 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.